Apatinib in refractory radiation-induced brain edema: A case report.
Märksõnad
Abstraktne
BACKGROUND
Apatinib is a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor receptor-2, which has observed to be effective and safe in refractory radiation-induced brain edema, like Avastin did. Till now, there is no case report after apatinib came in the market.
UNASSIGNED
Two patients who received brain radiotherapy developed clinical manifestations of brain edema, including dizziness, headache, limb activity disorder, and so on.
UNASSIGNED
Two patients were both diagnosed as refractory radiation-induced brain edema.
METHODS
Two patients received apatinib (500 mg/day) for 2 and 4 weeks.
RESULTS
Two patients got symptomatic improvements from apatinib in different degrees. Magnetic resonance imaging after apatinib treatments showed that compared with pre-treatment imaging, the perilesional edema reduced dramatically. However, the toxicity of apatinib was controllable and tolerable.
CONCLUSIONS
Apatinib can obviously relieve the symptoms of refractory radiation-induced brain edema and improve the quality of life, which offers a new method for refractory radiation-induced brain edema in clinical practices. But that still warrants further investigation in the prospective study.
